Norton Children’s Research Institute, affiliated with the UofL School of Medicine, is involved in a study of nirmatrelvir/ritonavir (authorized as Paxlovid in older children and adults) in symptomatic pediatric outpatients with COVID-19 who are at risk of progression to severe illness.
Norton Children’s Research Institute, affiliated with the UofL School of Medicine, is involved in a study to evaluate the safety, pharmacokinetics and efficacy of nirmatrelvir/ritonavir (authorized as Paxlovid in older children and adults) in symptomatic pediatric outpatients with COVID-19 who are at risk of progression to severe illness. All participants will receive the study medication, which is taken orally twice a day for five days. Participants’ total time in the study will be about five weeks.
For providers with access to Norton Healthcare’s Epic medical records system, there is a best practice alert (BPA) in Epic to help identify potential participants from general pediatric practices, emergency departments and Norton Immediate Care Centers. If you see the BPA, please consider referring the patient to our research team to evaluate their eligibility for the study, NCT05261139.
